The global Biologics Outsourcing market was worth around USD 11,285.4 million in 2021 and is estimated to grow to about USD 23620.6 million by 2028, with a compound annual growth rate (CAGR) of approximately 13.1 percent over the forecast period.
The global Biologics Outsourcing market was worth around USD 11,285.4 million in 2021 and is estimated to grow to about USD 23620.6 million by 2028, with a compound annual growth rate (CAGR) of approximately 13.1 percent over the forecast period. The report analyzes the Biologics Outsourcing market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Biologics Outsourcing market.
Biologics Outsourcing Market: Overview
Biologics Outsourcing services are expected to see a massive increase in popularity over the forecast period owing to rising investments in biotechnology research and development activities across the world. Biologics are drugs that are directly procured from living organisms and are extensively used in the treatment of multiple chronic diseases across the world.
These drugs are seeing a substantial increase in demand and are expected to be highly popular over the forecast period. They are also seeing an increase in use for the treatment of cardiovascular diseases which have massively increased in incidence over the past few years.
Biologics Outsourcing companies are expected to see good growth in business and revenue over the forecast period as the advancements in the healthcare sector boost. An increasing geriatric population is also expected to boost the market for Biologics Outsourcing over the forecast period.
The COVID-19 pandemic had a significantly adverse impact on the Biologics Outsourcing market. The Biologics Outsourcing services saw a drop in demand owing to changing world landscape under the lockdown restrictions that were imposed across the world to contain the spread of infections. However, the Biologics Outsourcing market did also experience some increase in demand as multiple vaccine development programs were outsourced to small biotechnology companies and hence kept the Biologics Outsourcing market afloat during the pandemic.
The Biologics Outsourcing market is anticipated to rise at its full potential over the forecast period from the post-pandemic era as the lockdown restrictions are lifted and the world returns to normal. The Biologics Outsourcing market will see a high influx of investments in the research and development sector and hence drive the Biologics Outsourcing growth through 2028.
Biologics Outsourcing Market: Growth Drivers
Increasing Focus on Healthcare to Boost growth
Advancements in the healthcare industry have been prevalent across the world and this trend is expected to majorly boost the Biologics Outsourcing market potential over the forecast period. The Biologics Outsourcing market is also expected to be driven by the increasing prevalence of chronic diseases and rising instances of cancers, cardiovascular diseases, etc. increasing geriatric population across the world will also favor the Biologics Outsourcing market potential through 2028. Rising spending on research and development activities by healthcare companies and governments as well are expected to boost the Biologics Outsourcing market potential over the forecast period.
Global Biologics Outsourcing Market: Segmentation
The global Biologics Outsourcing market is segregated based on type, source, application, and region.
By type, the market is divided into Antibodies, Monoclonal Antibodies, Antibody Drug Conjugates, Others, Recombinant Proteins, Vaccines, and Others. The vaccine segment is anticipated to see high growth over the forecast period owing to the rising demand for vaccines for multiple diseases.
By Application, the Biologics Outsourcing market is segmented into Stem Cell Research, Vaccine Development, Tissue Related Products development, and Others. The stem cell research and vaccine development segments are projected to see high demand over the forecast period owing to rising investments in this sector by multiple healthcare companies and governments.
|Historic Years||2016 - 2020|
|Forecast Years||2021 - 2028|
|Segments Covered||By Product Type, By Application, and By End Use|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Quantitative Units||Revenue in USD million/billion and CAGR from 2021 to 2028|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World|
|Countries Covered||U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others|
|Number of Companies Covered||10 companies with scope for including additional 15 companies upon request|
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.|
|Customization Scope||Avail customized purchase options to meet your exact research needs.|
the presence of a developed healthcare infrastructure the Biologics Outsourcing market in North America is expected to hold a dominant outlook over the forecast period. Increasing investments on research and development activities in North America is expected to be a prominent driver through 2028. Rising support from the government, increasing adoption of technology in healthcare, favorable reimbursement initiatives, and increasing demand for quality diagnostics and treatment are other factors that will drive the Biologics Outsourcing market growth over the forecast period. The United States is anticipated to be the most lucrative country in this region through 2028. Europe is anticipated to follow North America and be the second largest market for Biologics Outsourcing in the global landscape. Increasing research and development activities will also favor Biologics Outsourcing market growth through 2028.
The Asia Pacific is anticipated to be the fastest-growing Biologics Outsourcing market in the global Biologics Outsourcing industry landscape over the forecast period.
Some of the main competitors dominating the global Biologics Outsourcing market include – Catalent, Inc., Lonza Group AG, Wuxi Biologics, Boehringer Ingelheim, Abzena Limited, GL Biochem Corporation
Global Biologics Outsourcing market is segmented as follows:
This report is based on in-depth qualitative and quantitative analyses of the global Biologics Outsourcing market. Zion Market Research has collected and analyzed key data belong to the global Biologics Outsourcing market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.
The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.
Various parameters have been taken into account, while estimating market size. The revenue generated by the leading industry participants in from the sales of Biologics Outsourcingacross the world has been calculated through primary and secondary research.
Zion Market Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc.
For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the Biologics Outsourcing industry. Primary research makes up the major source of data collection and validation.
We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:
Participants who typically participate in such a process include, but are not limited to:
Key opinion leaders specializing in different areas corresponding to different industry verticals
Secondary research sources that are typically referred to include, but are not limited to:
News articles, press releases and webcasts specific to companies operating in the market
Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Biologics Outsourcing market.
Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:
Increasing investment in research and development and rising focus on healthcare are some major trends that guide Biologics Outsourcing market growth.
According to the Market Research report, the global Biologics Outsourcing market was worth about US$ 11,285.4 million in 2021 and is predicted to grow to around US$ 23620.6 million by 2028, with a compound annual growth rate (CAGR) of around 13.1 percent.
the presence of a developed healthcare infrastructure the Biologics Outsourcing market in North America is expected to hold a dominant outlook over the forecast period. Increasing spending on research and development activities in this region is expected to be a prominent driver through 2028.